ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Jeff, they obviously have their reasons,. We just don't see or understand it, yet.

Possible reasons could include one or more of the following:
1) The testosterone partner is taking intent on taking a stake in ANIP. ANIP would not try to drive up PPS during this period.
2) A partner is in control an NDA filing for testosterone and ANIP just has to sit on its hands until the announcements are made.
3) It could be part of a larger deal.
4) Waiting until the CVR's have expired.
5) Lower strike price in stock options being awarded.

In any event, I find it hard to believe that ANIP won't benefit in some way from the Libigel data. Especially in light of the projected growth in hormone therapy gong from $31 billion (2021) to $53.9 billion (2030) much of related to menopausal women.

https://ca.sports.yahoo.com/news/hormone-replacement-therapy-market-size-140000657.html" rel="nofollow" target="_blank" >Hormone Replacement Therapy Market Size to Hit USD 53.9 Bn by 2030